Cover Image

Levosimendan in acute heart failure with severely reduced kidney function, a propensity score matched registry study

Patients with heart failure frequently present with kidney dysfunction. Kidney function is relevant, as prognosis declines with reduced kidney function and potentially beneficial drugs like levosimendan are contraindicated for missing safety data.Materials and methodsA single-center retrospective re...

Full description

Saved in:
Bibliographic Details
Main Authors: Rottmann, Felix (Author) , Breiden, Ann Katrin (Author) , Bemtgen, Xavier (Author) , Welte, Thomas (Author) , Supady, Alexander (Author) , Wengenmayer, Tobias (Author) , Staudacher, Dawid (Author)
Format: Article (Journal)
Language:English
Published: 20 October 2022
In: Frontiers in Cardiovascular Medicine
Year: 2022, Volume: 9, Pages: 1-12
ISSN:2297-055X
DOI:10.3389/fcvm.2022.1027727
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3389/fcvm.2022.1027727
Verlag, Volltext: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1027727
Get full text
Author Notes:Felix Arne Rottmann, Ann Katrin Breiden, Xavier Bemtgen, Thomas Welte, Alexander Supady, Tobias Wengenmayer and Dawid Leander Staudacher
Description
Summary:Patients with heart failure frequently present with kidney dysfunction. Kidney function is relevant, as prognosis declines with reduced kidney function and potentially beneficial drugs like levosimendan are contraindicated for missing safety data.Materials and methodsA single-center retrospective registry study was conducted including all patients receiving levosimendan on a medical intensive care unit between January 2010 and December 2019. Exclusion criteria were a follow-up less than 24 h or missing glomerular filtration rate (eGFR) before administration of levosimendan. The first course of treatment was evaluated. Patients were stratified by eGFR before drug administration and the primary endpoint was a composite of supraventricular-, ventricular tachycardia and death within 7 days after administration of levosimendan. An internal control group was created by propensity score matching.
Item Description:Gesehen am 25.01.2023
Physical Description:Online Resource
ISSN:2297-055X
DOI:10.3389/fcvm.2022.1027727

Similar Items